Recent Analysts’ Ratings Updates for LivaNova (LIVN)

A number of research firms have changed their ratings and price targets for LivaNova (NASDAQ: LIVN):

• 5/2/2024 – LivaNova had its price target raised by analysts at Robert W. Baird from $58.00 to $66.00. They now have a “neutral” rating on the stock.
• 5/2/2024 – LivaNova had its price target raised by analysts at Mizuho from $75.00 to $80.00. They now have a “buy” rating on the stock.
• 5/1/2024 – LivaNova had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
• 4/25/2024 – LivaNova was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 4/17/2024 – LivaNova was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 3/27/2024 – LivaNova had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $75.00 price target on the stock.
• 3/20/2024 – LivaNova had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.

LivaNova Trading Down 2.4 %

NASDAQ LIVN opened at $62.60 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.71 and a current ratio of 3.17. LivaNova PLC has a one year low of $42.75 and a one year high of $64.47. The company has a 50-day simple moving average of $54.84 and a 200-day simple moving average of $51.16. The firm has a market capitalization of $3.39 billion, a PE ratio of -104.33 and a beta of 0.92.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 1st. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28. The company had revenue of $294.90 million during the quarter, compared to the consensus estimate of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. LivaNova’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 earnings per share. On average, equities analysts forecast that LivaNova PLC will post 3.01 earnings per share for the current year.

Hedge Funds Weigh In On LivaNova

Several hedge funds and other institutional investors have recently modified their holdings of LIVN. Louisiana State Employees Retirement System acquired a new position in LivaNova during the 4th quarter valued at about $781,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of LivaNova by 10.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,384 shares of the company’s stock valued at $641,000 after buying an additional 1,208 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of LivaNova during the third quarter worth approximately $7,932,000. Kingdon Capital Management L.L.C. bought a new position in LivaNova in the 3rd quarter worth approximately $7,123,000. Finally, Vanguard Group Inc. increased its position in LivaNova by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock valued at $93,612,000 after acquiring an additional 100,133 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.